RAPID-CKD Phase 4 Trial, Simultaneous 4 Guideline-Directed CKD Therapies
ClinicalTrials.gov Studies
Summary
NIH registered Phase 4 clinical trial NCT07547878 on April 23, 2026, evaluating simultaneous initiation of four guideline-directed chronic kidney disease therapies in patients with Type 2 Diabetes. The 20-drug intervention list includes finerenone, semaglutide, 6 ACE inhibitors, 7 ARBs, and 6 SGLT2 inhibitors. Study hypothesis: starting all four medication classes together is safe and effective for reducing albuminuria without kidney function decline or elevated potassium.
“The purpose of this study is to determine if starting all four chronic kidney disease therapies at the same time is safe and effective in patients with Type 2 Diabetes and Chronic Kidney Disease.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH registered the RAPID-CKD Phase 4 clinical trial (NCT07547878) on ClinicalTrials.gov, making the study protocol publicly available. The trial will enroll patients with Type 2 Diabetes and Chronic Kidney Disease to test whether starting all four guideline-directed therapy classes simultaneously is safe compared to sequential initiation.
Healthcare providers and clinical investigators interested in CKD drug development should note the broad intervention list: finerenone, semaglutide, 6 ACE inhibitors, 7 ARBs, and 6 SGLT2 inhibitors. The composite endpoint focuses on albuminuria reduction, kidney function preservation, and potassium level stability. Trial sponsors and clinical sites may wish to review eligibility criteria directly on ClinicalTrials.gov.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
Phase 4 NCT07547878 Kind: PHASE4 Apr 23, 2026
Abstract
The purpose of this study is to determine if starting all four chronic kidney disease therapies at the same time is safe and effective in patients with Type 2 Diabetes and Chronic Kidney Disease. Study hypothesis states that starting all four recommended kidney medications at the same time is safe and effective in reducing albuminuria, a protein in the urine, without a decline in kidney function or increase in potassium levels compared to starting one medication at a time.
Conditions: Chronic Kidney Diseases, Type 2 Diabetes
Interventions: Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.